IQ EQ FUND MANAGEMENT IRELAND Ltd Makes New Investment in Natera, Inc. (NASDAQ:NTRA)

IQ EQ FUND MANAGEMENT IRELAND Ltd bought a new stake in Natera, Inc. (NASDAQ:NTRA) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm bought 1,959 shares of the medical research company’s stock, valued at approximately $249,000.

Several other hedge funds have also recently bought and sold shares of the company. Creative Planning increased its holdings in Natera by 18.3% in the 3rd quarter. Creative Planning now owns 5,833 shares of the medical research company’s stock valued at $740,000 after buying an additional 904 shares during the period. Exchange Traded Concepts LLC increased its holdings in Natera by 30.5% in the 3rd quarter. Exchange Traded Concepts LLC now owns 12,064 shares of the medical research company’s stock valued at $1,532,000 after buying an additional 2,821 shares during the period. CWM LLC increased its holdings in Natera by 119.5% in the 3rd quarter. CWM LLC now owns 15,441 shares of the medical research company’s stock valued at $1,960,000 after buying an additional 8,406 shares during the period. Connective Portfolio Management LLC increased its holdings in Natera by 40.6% in the 3rd quarter. Connective Portfolio Management LLC now owns 9,000 shares of the medical research company’s stock valued at $1,143,000 after buying an additional 2,600 shares during the period. Finally, Royal Fund Management LLC increased its holdings in Natera by 85.9% in the 3rd quarter. Royal Fund Management LLC now owns 15,800 shares of the medical research company’s stock valued at $2,006,000 after buying an additional 7,300 shares during the period. 99.90% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Morgan Stanley raised their target price on shares of Natera from $125.00 to $132.00 and gave the company an “overweight” rating in a report on Tuesday, August 13th. BTIG Research lifted their price target on shares of Natera from $125.00 to $135.00 and gave the company a “buy” rating in a report on Friday, August 9th. Canaccord Genuity Group lifted their price target on shares of Natera from $130.00 to $145.00 and gave the company a “buy” rating in a report on Tuesday, August 27th. Stephens reaffirmed an “overweight” rating and set a $125.00 price target on shares of Natera in a report on Friday, August 9th. Finally, StockNews.com raised shares of Natera from a “sell” rating to a “hold” rating in a report on Thursday. One investment analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $124.44.

Natera Stock Down 3.5 %

Shares of NASDAQ NTRA opened at $122.35 on Friday. The company has a market capitalization of $15.02 billion, a P/E ratio of -39.21 and a beta of 1.53. Natera, Inc. has a 52-week low of $36.90 and a 52-week high of $133.54. The company has a debt-to-equity ratio of 0.34, a quick ratio of 4.01 and a current ratio of 4.14. The company’s 50 day moving average price is $122.85 and its 200-day moving average price is $110.07.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.39. The firm had revenue of $413.35 million for the quarter, compared to the consensus estimate of $343.00 million. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The company’s revenue for the quarter was up 58.1% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.97) EPS. Equities analysts forecast that Natera, Inc. will post -1.96 earnings per share for the current year.

Insider Activity at Natera

In related news, CEO Steven Leonard Chapman sold 4,523 shares of the business’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $130.40, for a total transaction of $589,799.20. Following the transaction, the chief executive officer now owns 191,163 shares in the company, valued at $24,927,655.20. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Steven Leonard Chapman sold 4,523 shares of the business’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $130.40, for a total transaction of $589,799.20. Following the transaction, the chief executive officer now owns 191,163 shares in the company, valued at $24,927,655.20. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Solomon Moshkevich sold 549 shares of the business’s stock in a transaction on Monday, July 22nd. The shares were sold at an average price of $105.16, for a total transaction of $57,732.84. Following the transaction, the insider now owns 113,637 shares in the company, valued at $11,950,066.92. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 50,765 shares of company stock worth $6,016,700 in the last quarter. Company insiders own 7.60% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.